


# Understanding glucose and the neonate

Joanna Benec, Meg Arppe-Robertson, Jordan Mann & Lela Yap



#### Glucose Infusion Rate (GIR) Calculation mg/kg/min

- NICU infusions usually run continuously over 24h
- Accordingly, can simplify equation:

#### GIR (mg/kg/min) = <u>rate (mL/h) x dextrose concentration (g/L)</u> dosing wt (kg) x 60 (minutes/h)

\* g/L equivalent to mg/mL

#### # 1: Baby F To use or not to use glucagon



https://mms.mckesson.com/product/1082180/Fresenius-USA-63323059303

- Baby F is born 35-weeks gestational age with a birth weight of 3.13 kg (92<sup>nd</sup> percentile).
- Maternal history is significant for Type II Diabetes requiring insulin.
- Baby F is transferred to a tertiary center for Persistent Pulmonary Hypertension (PPHN) management with central umbilical lines placed.
- She is made nil-per-oral and managed on a Total Fluid Intake (TFI) via intravenous (IV) line of 80ml/kg/day for asymptomatic hypoglycemia of 1.6mmol/L.
- Her IV fluid is Dextrose 20%.

Question: Baby F weighs 3.13 kg. Her TFI is 80 mL/kg/d and she is running D20W. What is her calculated GIR given this information?

a)5.9 mg/kg/min b)4.8 mg/kg/min c)8.2 mg/kg/min **d)11.1 mg/kg/min** 

#### # 1: Baby F


**Answer explained:** Whilst her calculated GIR is 11 mg/kg/min which would be very significant for 1<sup>st</sup> day following birth and warrant consideration of glucagon initiation, r**arely** is maintenance IVF the ONLY thing running.

This baby had the following infusions


- Heparin (in 0.45%NS) @ 2 mL/h via Umbilical lines for patency
- Morphine (in D5W) @ 1.57 mL/h for PPHN sedation

Thus actual **D20W** @ 6.8 mL/h to make up TFI 80 mL/kg/d

- GIR = 0 (heparin) + 0.4 (morphine) + 7.2 (D20W)
  - = 7.6 mg/kg/min



# #1: Baby F what happened



- Due to hypoglycemia and fluid management Glucagon was started late evening Day 1, on transport (red arrow on graph)
  - GIR 7.6 mg/kg/min
  - BG 6.1 mmol/L (TFI 80, D20W)
- The baby subsequently developed Hyperglycemic (8.2 mmol/L). Glucagon was discontinued at Day 2, 1000h after re-calculation of GIR
- Blood glucose levels were > 3.1 mmol/L for remainder of admission. Baby transitioned to full oral feeds successfully.

#1: Baby F – Discussion points						
Was glucagon infusion necessary?	Likely not					
Consider: access, TFI, fluid balance, IVF	<ul> <li>Central, 80 mL/kg/d, negative fluid balance, u/o 个 to 3.9 mL/kg/h while glucagon running</li> <li>Na most recently 130mmol/L however u/o 个 and no Na in IVF</li> </ul>					
Calculate: GIR	<ul> <li>GIR 7.1 mg/kg/min and BG manageable when glucagon was initiated (thus likely did not need to be started)</li> </ul>					
Be aware: prior to glucagon infusion, consider:	<ul> <li>GIR could be increased - higher TFI or dextrose concentration</li> <li>IV Dextrose Bolus options.</li> <li>Start and advance feeds (if appropriate)</li> </ul>					



# Current Evidence Based Guidelines

#### SICKKIDS NICU NUTRITION GUIDELINES\*

Dextrose Targets (mg/kg/min)						
Preterm Term						
Initial Dose*	5-8					
Advance Daily	1-2 1-3					
Acceptable Upper Limit	10-16	11-12				

\*https://torontocentreforneonatalhealth.com/wp-content/uploads/2020/10/SickKids-NICU-Nutrition-Guidelines-July-2020.pdf

# Normal GIR provision



 Usual rate of glucose utilization is 4-8 mg/kg/min.

Common caveats:

- Lower requirements: term cooled infants; acute sepsis.
- Higher or lower in extremely preterm infants .
- Action should be driven by <u>actual</u> intake (GIR) rather than assumptions based on dextrose concentration.

Target reduction or increase in GIR rather than switching dextrose concentration

#### Know your numbers... *Always calculate GIR*

IMPORTANT: Table assumes no other infusions are running – often NOT the case

SickKids NICU protocol if IVF > D12.5 = central access thus GIR will <u>often be lower</u> than noted below due to co-infusions.

GIR (mg/kg/min) using standard IVF concentrations									
TFI (mL/kg/d)	5% dextrose	10% dextrose	12.5% dextrose	15% dextrose	20% dextrose				
50	1.7	3.5	4.3	5.2	6.9				
60	2.1	4.2	5.2	6.3	8.3				
80	2.8	5.6	6.9	8.3	11.1				
100	3.5	6.9	8.7	10.4	13.9				
120	4.2	8.3	10.4	12.5	16.7				
140	4.9	9.7	12.2	14.6	19.4				
160	5.6	11.1	11.1 13.9		22.2				
Q20 mL/kg change	0.7	1.4	1.7	2.1	2.8				

Reacting to serum BG just by switching IVF without calculating can lead to inappropriate GIR provision

TAKEAWAYS

# 2: Baby S – Consider the impact of Medications




- Baby S is born 37-week gestational age with a birth weight of 2.95 kg.
- Acute postnatal period was significant for pneumothorax and suspected sepsis.
- Day 3 post birth Baby S has presumed sepsis with hypotension requiring epinephrine infusion prior to transport via Acute Care Transport Services (ACTS) SickKids.
- Blood glucose on admission was 11.6 mmol/L

Question: Baby S weighs 2.95 kg. Her D10W is running for TFI at 8.7 mL/hr. What is her GIR?

#### a)4.9 mg/kg/min

b)6.7 mg/kg/min c)8.8 mg/kg/min d)11.1 mg/kg/min

### # 2 Baby S – Glucose and Epinephrine timeline



### # 2 Baby S – Discussion points

Could hypoglycemia have been Yes avoided? Consider: BG trend, expected • BG dropped 11.6 to 5.6 mmol/L over 6h with epinephrine weans changes • Anticipate BG rise with epinephrine and drop as weaned off Calculate: GIR **KNOW THE GIR** Be aware: BG trends, GIR, and • BG values alone may not indicate the whole picture medications that impact • Where possible: act prophylactically in predictable glycemia control issues glycemia



# Medications/Conditions Affecting Glycemia

	Causes of HYPOglycemia	Causes of HYPERglycemia
Medications	<ul><li>PGEs</li><li>Propranolol</li></ul>	<ul><li>Epinephrine</li><li>Hydrocortisone</li><li>Dexamethasone</li></ul>
Conditions	<ul> <li>Prematurity</li> <li>Fetal Growth Restriction/IUGR</li> <li>LGA</li> <li>Maternal DM/GDM</li> <li>Maternal labetalol use</li> <li>Transient hyperinsulinism</li> <li>Perinatal asphyxia/stress</li> <li>Family hx IEM</li> <li>BWS, CAH, hypopituitarism</li> </ul>	<ul> <li>Sepsis</li> <li>Extreme prematurity</li> <li>Surgery/stress</li> </ul>
latrogenic	<ul><li>Inadequate substrate provision</li><li>Rapid discontinuation of IV dextrose</li></ul>	Excessive substrate provision

# 3: Baby O in hospital Don't forget glucose when correcting electrolytes

+

0

Baby O is post-op day 2 for ileostomy creation. He has gained 500g secondary to post-op edema and requirement of a significant amount of blood products. The TFI has been strictly set at 100 mL/kg/d to prevent further fluid accumulation and wound dehiscence. A concentrated PN solution with D24 runs to maintain blood glucose level. BID Lasix has been prescribed to help promote diuresis. However, the patient's potassium level is dropping because of the Lasix and he requires a potassium correction overnight. UO weighs 1.65 kg. He has a D24 in his PN. A high K+ has been ordered to run at 0.8 mL/hr (in D5\*0.45%NS) and included in TFI. To maintain TFI, PN is decreased by 0.8 mL/hr. What is the **net change** in GIR?

a)-0.3 mg/kg/min b)-1.5 mg/kg/min c)-2.1 mg/kg/min d)-0.8 mg/kg/min

#### #3: Baby O

#### TFI 100 mL/kg/day

- Infusions: Heparin (PAL, PICC), Morphine, SMOF Lipid
- Concentrated PN @4.3 mL/h
  - Dex 240 g/L = 10.4 mg/kg/min
  - K 50 mmol/L = 3.1 mmol/kg/d

K correctionstarted	on _					
Starteu	19:45	23:41	01:50	02:59	03:01	06:10
Lactato	2.1					2.2
Lactate	2.1					2.3
Sodium	141					146
Potassium	2.8	3.9	3.6			2.9
Chloride	112					113
Glucose	4.4		2.2	1.8	2.9	3.7
Creatinine						27
Urea						3.4
Albumin						22

## # 3: Baby O - Discussion

Consider: dextrose composition of PN and/or IVFs • Ideally check bedside pumps for accurate rates & compo	position
• GIR expected to have been acceptable at reduced rat	ite
<ul> <li>Be aware: Patient's historical tolerance to GIR changes</li> <li>GIR change &gt;1 mg/kg/min can be clinically significant</li> <li>Pt historically required high GIRs to maintain glucose control</li> </ul>	

### Fluid restriction often requires use of high dextrose concentration



- Check what dextrose concentration is running before reducing rate
- Post op watchout for the rebound hyperglycaemia!
  - Initial hyperglycemia then usually need to ↑ GIR once post-op stress hormones ↓
  - Compounded by needs pre-op to maintain serum glucose

# 4: Baby G *Consider rate relative for weight when changing IVF* 


- Baby G is born 26-weeks gestation, now day 3 post birth and on a TFI 200 mL/kg/day. Her dosing weight is 600 grams.
- She is currently with adrenal insufficiency requiring hydrocortisone (0.5 mg/kg/dose q12h) and has a peripheral arterial line (PAL) with heparin 1ml/hr for haemodynamic monitoring.
- Her PAL is removed at 1800h and Dextrose 10%/Saline 0.2% is hung overnight.

Question: Baby G (0.6 kg) has a PAL in situ running at 1 mL/hr. This heparin makes up:

a)10 mL/kg/d b)40 mL/kg/d c)20 mL/kg/d d)5 mL/kg/d Question: Baby G's PAL is running 1 mL/hr Heparin (in 0.45%NS); the PAL is removed and 1 mL/hr D10W\*0.2%NS is run for TFI. Baby's dosing weight is 0.6 kg. What is the effect on GIR?

a)+0.8 mg/kg/min
b)+1.1 mg/kg/min
c)-0.5 mg/kg/min
d)+2.8 mg/kg/min

### #4: Baby G - outcome



- With the increased GIR baby G had iatrogenic rapid hyperglycemia with serum glucose values normalizing once a New parenteral nutrition fluid bag was ordered and commenced early.
- Interim management was, increased rate of heparin running through her PICC line

#4: Baby G — di	scussion points
Was hyperglycemia preventable?	• Perhaps
<b>Consider</b> : rate compared to weight	<ul><li>1 mL/h = 40 mL/kg/d</li><li>Significant!</li></ul>
Calculate: GIR & ∆ GIR	<ul> <li>1 mL/h with D10W = 2.8 mg/kg/min</li> <li>27% increase in GIR – now total 13.2 mg/kg/min</li> </ul>
Review: patient's historical tolerance to GIR changes	<ul> <li>GIR &gt; 1 mg/kg/min can be clinically significant</li> <li>Historically had BG trending high, climbing with GIR increases, HC</li> </ul>

# (Dosing) Weight Matters



Wt (kg)	TFI (ml/kg/d)	D10W at 1 ml/hr Change in GIR (mg/kg/min)	Check impact of the change in
0.5	48	3.3	IV fluids relative to pt's wt
0.75	32	2.2	
1	24	1.7	
1.25	19	1.3	It's only 1 mL
1.5	16	1.1	or is it?
2.5	10	0.7	
3	8	0.6	

#### Prematurity & Glycemic Control



HYPOglycemia	HYPERglycemia
Immaturity of counter- regulatory hormone systems	Inability to suppress hepatic glucose production
Poor nutrient stores (low glycogen stores)	Insulin resistance
latrogenic	Glucose intolerance
	latrogenic

- ↑ risk of abnormal blood sugars especially if extremely premature +/- IUGR
- Clinical and scientific literature and extensive common experience document many adverse outcomes associated with neonatal hyperglycemia, including increased mortality, worse retinopathy of prematurity, brain white matter injury, reduced neuronal density and synapse formation, adverse neurologic outcomes, and reduced long-term growth

The long-term effects of neonatal hypoglycemia have been studied extensively. Most notably, there is a known relationship between neonatal hypoglycemia and long-term neurodevelopmental outcomes. See the following references for more information. These articles represent only a small proportion of the published literature examining neonatal hypoglycemia.

Research

JAMA Pediatrics | Original Investigation

#### Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years

Christopher J. D. McKinlay, PhD; Jane M. Alsweiler, PhD; Nicola S. Anstice, PhD; Nataliia Burakevych, PhD; Arijit Chakraborty, PhD; J. Geoffrey Chase, PhD; Gregory D. Gamble, MSc; Deborah L. Harris, PhD; Robert J. Jacobs, PhD; Yannan Jiang, PhD; Nabin Paudel, PhD; Ryan J. San Diego, MSc; Benjamin Thompson, DPhil; Trecia A. Wouldes, PhD; Jane E. Harding, DPhil; for the Children With Hypoglycemia and Their Later Development (CHYLD) Study Team

Auckland, New Zealand

Reviews

Systematic Review and Meta-Analysis

Neonatology

**Neonatal Glycaemia and** 

**Neurodevelopmental Outcomes:** 

Rajesh Shah<sup>a</sup> Jane Harding<sup>a</sup> Julie Brown<sup>a</sup> Christopher McKinlay<sup>a-c</sup> <sup>a</sup>Liggins Institute, University of Auckland, Auckland, New Zealand; <sup>b</sup>Department of Paediatrics: Child and Youth

**A Systematic Review and Meta-Analysis** 

Health, University of Auckland, Auckland, New Zealand; <sup>c</sup>Kidz First Neonatal Care, Counties Manukau Health,

Neonatology 2019;115:116-126 DOI: 10.1159/000492859

Received: July 24, 2018 an: August 12 2015 shed online: November 8, 2

THE JOURNAL OF PEDIATRICS • www.jpeds.com



Relationship between Measures of Neonatal Glycemia, Neonatal Illness, and 2-Year Outcomes in Very Preterm Infants

Anna Catherine Tottman, MBBS<sup>1</sup>, Jane Marie Alsweiler, PhD<sup>2,3</sup>, Frank Harry Bloomfield, PhD<sup>1,3</sup>, Maggie Pan<sup>2</sup>, and Jane Elizabeth Harding, DPhil<sup>1</sup>

#### Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia

A Lucas, R Morley, T J Cole

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

#### Neonatal Glycemia and Neurodevelopmental **Outcomes at 2 Years**

Christopher J.D. McKinlay, Ph.D., Jane M. Alsweiler, Ph.D., Judith M. Ansell, Ph.D., Nicola S. Anstice, Ph.D., J. Geoffrey Chase, Ph.D., Gregory D. Gamble, M.Sc., Deborah L. Harris, Ph.D., Robert J. Jacobs, Ph.D., Yannan Jiang, Ph.D., Nabin Paudel, B.Optom., Matthew Signal, Ph.D., Benjamin Thompson, D.Phil., Trecia A. Wouldes, Ph.D., Tzu-Ying Yu, Ph.D., and Jane E. Harding, D.Phil., for the CHYLD Study Group\*

**Neurologic Aspects of Neonatal Hypoglycemia** 

Arie L. Alkalay MD<sup>1</sup>, Harvey B. Sarnat MD<sup>2\*</sup>, Laura Flores-Sarnat MD<sup>2\*</sup> and Charles F. Simmons MD<sup>1</sup> Divisions of <sup>1</sup>Neonatology and <sup>2</sup>Neurology, Department of Pediatrics, Ahmanson Pediatric Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA Affiliated to David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

#5: Baby R *Practice calculating GIR* & *implementing an appropriate plan* 

- Baby R is born at term gestation with small for gestation age birth weight of 2.83kg and antenatal suspicion of Ompahlocele, clinically confirmed after birth.
- He undergoes uncomplicated repair and is now with return of bowel function a few days post-operative and able to trial oral feeds.
- He has a history of hypoglycemia and is currently on a TFI of 160ml/kg/day = 18.9 mL/h
  - PN (D14) @13.9 mL/h
  - EBM @8mL Q3h (incr 1 mL q6h)

# Question: what is the carbohydrate content of EBM

- A) 105 g/L
- B) 90 g/L
- C) 72 g/L
- D) 65 g/L

#### #5: Baby R

	Nutrient Content per Litre											
		Expressed Breast Milk (EBM)				Standard Formulas				Therapeutic Formulas		
NICU Yellow card	Nutrient	Mature EBM (Donor EBM)	EBM +Sim	Fortified EBI	M: EBM + EnfaCare	Enfami Prema (Preterm F	ture	Enfamil A+ EnfaCare (Post- Discharge Formula)	Enfam (Term F		Good Start (Whey)	PURAMINO A+ (Free AA)/ Nutramigen A+ (Hydrolyzed Casein)
NICO fellow card	Concentration kcal/ml	0.68	0.74 (1pk HMF: 50ml EBM)	0.8 (1pk HMF: 25ml EBM)	0.8	0.68	0.8	0.74	.0.68	0.8	0.67	0.68
©The Hospital for Sick Children. All Rights Reserved. SickKids does not accept responsibility for use of this material by any person or organization not associated with SickKids. No part of this document should be used for publication without appropriate acknowledgement.	Energy kcal/L	680	745	800	809	680	810	740	680	810	670	680
	Protein	12 (9)	20.0	26.7	15.8	20	24	21	14	17	15	18.9
	Fat g/L	39	39.3	39.5	46	34	41	39	36	43	34	36
	Carbohydrate	72	79.1	85.0	85	74	89	77	76	88	75	72/70
	Sodium mmol/L	7.8	11.1	13.8	9.9	17.1	20	11.3	7.9	9.5	7.8	13.8

What is the current PN GIR?						
<u>(13.9 mL/h x 140 g/L)</u>						
(60 min/h x 2.83 kg)						
= 11.5 mg/kg/min						

What is the current enteral GIR?
 Note: EBM has 72g/L CHO

 (8/3 mL/h x 72 g/L)
 (60 min/h x 2.83 kg)

= 1.1mg/kg/min

https://torontocentreforneonatalhealth.com/wp-content/uploads/2020/10/SickKids-NICU-Nutrition-Guidelines-July-2020.pdf



Gen Surg gives go ahead to  $\uparrow$  feeds 3mL Q3h...

How much will the GIR decrease by with each feed increase?
Note: 3 mL Q3h = 1 mL/h (1 mL/h x (72-140) g/L) (60 min/h x 2.83 kg) = -0.4 mg/kg/min

Net GIR change in 24h:
 -0.4 mg/kg/min x 8 feeds/d
 = -3.2 mg/kg/min

There are many options this baby could have, keep the wider "big picture" goals in mind when forming a plan.



Consider feed increases <u>below</u> protocol with hx hypoglycemia

- Especially if significant discrepancy between IV and feed CHO content
- If BG stable, can reassess to advance more quickly

#### If hypoglycemia persists:

- 1) Slow feed increases
- Increase TFI and decrease dextrose concentration to bridge discrepancy between IV and feed CHO content
- 3) Change to q2h feeds
- 4) Increase feed duration
- 5) Fortification (eg. PolyCal)



**Be aware:** fluids are titrated at the feed following increase

# 6: Baby P Selecting appropriate fluids on admission

Baby P is born 28-weeks gestation with a birth weight of 1.28 kg (88%ile Fenton)

- ACTS use D10W en-route from an outborn center to tertiary neonatal center
- She is admitted @ ~2200h (~7.5hrs of life) to the tertiary neonatal center.

# Question: What fluids would you order on admission?

•D10

• Electrolyte Free PN

•SMOF (soybean oil, medium-chain triglycerides, olive oil, fish oil) lipids + Electrolyte Free PN

#### Evidence Based Recommendations



**NICU Nutrition Guidelines** 

BW <1.5kg	BW >1.5kg
Start Electrolyte Free PN + SMOF at 1 g/kg/d *within first 24h of life*	Start 25/100 +/- SMOF 25= Amino Acids 25g/L 100 = Dextrose 100gm/L

Both available 24h/d and safe for PIV at many Level 2 and higher neonatal centers.


Recommendations for first day of life (ESPGHAN, 2018):

- Start amino acid provision (min 1.5 g/kg/d)
- Start lipid emulsion
- Provide minimum 45-55 kcal/kg/d

TFI 80 mL/kg/d = 4.3 mL/h hep @ 0.5 mL/h via UVC	D10W @ 3.8 mL/h	Sickkids Electrolyte Free PN @ 3.8 mL/h	SickKids Electrolyte Free PN @ 3.5 mL/h + SMOF @ 0.3 mL/h
Glucose Content (g/L)	100	100	100
GIR (mg/kg/min)	4.9	4.9	4.6
Protein Content (g/L)	-	25	25
Protein (g/kg/d)	-	1.8	1.6
Calcium Content (mmol/L)	-	12	12
Calcium (mmol/kg/d)	-	0.86	0.79
Fat (g/kg/d)	-	-	1.1
Energy (kcal/kg/d)	24	31	40
	Good	Better	Best

There are not many contraindications within first 24hrs

- Glycemic control/access issues requiring >D10
- Closer to the end of first 24h, already diuresing, requiring some electrolytes



Know the WEIGHT, RATE and SUBSTRATE

CALCULATE before you TITRATE/MEDICATE\*



- https://torontocentreforneonatalhealth.com/wp-content/uploads/2020/10/SickKids-NICU-Nutrition-Guidelines-July-2020.pdf
- Larsson LE, Nilsson K, Niklasson A et al. Influence of fluid regimens on perioperative blood-glucose concentrations in neonates. Br J Anaesth 1990; 64: 419–424.
- Joosten K, Embleton N, Yan W, Senterre T, & the ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Energy. Clin Nutr ESPEN. 2018 Dec;37(6 Pt B):2309-2314
- Rozance, Paul J. Management and outcome of neonatal hypoglycemia. UpToDate. Feb 2021
- Stark Ann R, Simmons R. Neonatal hyperglycemia. UpToDate. Feb 2021.
- Narvey M and Marks S. The screening and management of newborns at risk for low blood glucose. Canadian Paediatric Society, Fetus and Newborn Committee. Paediatr Child Health 2019 24(8):536–544.
- Mesotten D, Joosten K, van Kempen A, Verbruggen S; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Carbohydrates. Clin Nutr. 2018 Dec;37(6 Pt B):2337-2343. doi: 10.1016/j.clnu.2018.06.947. Epub 2018 Jun 18.
- Ramel S, Rao R. Hyperglycemia in Extremely Preterm Infants. Neoreviews. 2020 Feb;21(2):e89-e97. doi: 10.1542/neo.21-2-e89.
- Committee on Fetus and Newborn, Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011 Mar;127(3):575-9. doi: 10.1542/peds.2010-3851. Epub 2011 Feb 28.
- Alkalay AL, Sarnat HB, Flores-Sarnat L, Simmons CF. Neurologic aspects of neonatal hypoglycemia. Isr Med Assoc J. 2005 Mar;7(3):188-92. Erratum in: Isr Med Assoc J. 2005 Apr;7(4):267.
- Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia. BMJ. 1988 Nov 19;297(6659):1304-8. doi: 10.1136/bmj.297.6659.1304
- McKinlay CJD, Alsweiler JM, Ansell JM, Anstice NC, Chase JG, Gamble GD, Harris DL, et al. Neonatal glycemia and neurodevelopmental outcomes at 2 years. N Engl J Med. 2015 Oct;373:1507-1518.
- McKinlay CJD, Alsweiler JM, Anstice NS, Burakevych N, Chakraborty A, Chase JG, Gamble GD, Harris DL, Jacobs RJ, Jiang Y, Paudel N, San Diego RJ, Thompson B, Wouldes TA, Harding JE; Children With Hypoglycemia and Their Later Development (CHYLD) Study Team. Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years. JAMA Pediatr. 2017 Oct 1;171(10):972-983. doi: 10.1001/jamapediatrics.2017.1579.
- Shah R, Harding J, Brown J, McKinlay C. Neonatal Glycaemia and Neurodevelopmental Outcomes: A Systematic Review and Meta-Analysis. Neonatology. 2019;115(2):116-126. doi: 10.1159/000492859. Epub 2018 Nov 8. PMID: 30408811.
- Tottman, Anna & Alsweiler, Jane & Bloomfield, Frank & Pan, Maggie & Harding, Jane. (2017). Relationship between Measures of Neonatal Glycemia, Neonatal Illness, and 2-Year Outcomes in Very Preterm Infants. The Journal of Pediatrics. 188. 10.1016/j.jpeds.2017.05.052